PRIME

• Research type

  Research Study

• Full title

  A Phase II/III Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine (Menveo) or Glaxosmithkline Meningococcal ACWY Conjugate Vaccine in Adolescents Who Were Primed with Meningitec, Menjugate or Neisvac-C During Preschool Vaccination

• IRAS ID

  56109

• Contact name

  Elizabeth Miller

• Eudract number

  2010-022505-18

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  NCT01192997

• Research summary

  There is concern regarding waning immunity in individuals vaccinated against meningitis C as a part of the infant immunisation schedule. The intention of this study is to invite participants of a previous NVEC clinical trial (PreSchool Men C trial) to enrol to receive one of two new Meningitis ACWY vaccines to look at the boosting affect they will confer for Men C and the additional protection they will give for the other three serogroups (ACY and W135).

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  11/H1002/6

• Date of REC Opinion

  17 Oct 2011

• REC opinion

  Further Information Favourable Opinion